Mesoblast (NASDAQ:MESO) Stock Price Up 10.2%

Mesoblast Limited (NASDAQ:MESO)’s stock price traded up 10.2% during trading on Wednesday . The company traded as high as $7.37 and last traded at $7.27. 78,313 shares traded hands during trading, a decline of 95% from the average session volume of 1,727,138 shares. The stock had previously closed at $6.60.

Wall Street Analyst Weigh In

A number of research firms recently commented on MESO. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research report on Friday, January 12th. StockNews.com raised Mesoblast from a “sell” rating to a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.67.

Mesoblast Stock Up 1.1 %

The firm has a fifty day moving average of $4.19 and a two-hundred day moving average of $2.87.

Hedge Funds Weigh In On Mesoblast

Several institutional investors and hedge funds have recently added to or reduced their stakes in MESO. Lazari Capital Management Inc. grew its holdings in Mesoblast by 9.3% in the third quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock worth $116,000 after purchasing an additional 8,000 shares during the last quarter. Prosperity Wealth Management Inc. acquired a new stake in Mesoblast in the 3rd quarter worth approximately $79,000. Finally, Chase Investment Counsel Corp purchased a new stake in Mesoblast during the 1st quarter worth approximately $298,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.